SCHEMBL1284832

SCHEMBL1284832

CN1CCC(O)(c2ccc(Nc3ncc4ccn(C(CC(N)=O)C5(C(=O)O)CCC5)c4n3)cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 1/20 0.38
▸ CDK4 P11802 6/20 0.38
▸ CCND1 P24385 4/20 0.38
▸ CCND2 P30279 4/20 0.38
▸ CCND3 P30281 4/20 0.38
▸ FGFR4 P22455 3/20 0.37
▸ JAK2 O60674 3/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ MAP3K7 O43318 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.37
▸ JAK1 P23458 7/20 0.37
▸ AURKA O14965 2/20 0.37
▸ CDK1 P06493 2/20 0.37
▸ INSR P06213 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ FLT4 P35916 1/20 0.37
▸ KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1284495 0.89 JAK2 (0.38) JAK3CDK4CCND1CCND2CCND3
SCHEMBL1284285 0.88 CDK4 (0.51) JAK3CDK4CCND1CCND2CCND3
SCHEMBL1285557 0.87 STAT6 (0.48) JAK3JAK2BRD4FLT4KDR
SCHEMBL1285257 0.86 PTK2 (0.43) JAK3SRCWEE1PLK1
SCHEMBL1285380 0.85 JAK3 (0.47) JAK3CDK4CCND1CCND2CCND3
SCHEMBL1284416 0.83 JAK3 (0.49) JAK3JAK2JAK1FLT4KDR
SCHEMBL1285114 0.83 JAK3 (0.45) JAK3CDK4CCND1CCND2CCND3
SCHEMBL1284506 0.83 CAMK2D (0.43) JAK3CDK4CCND1CCND3JAK2
SCHEMBL1284543 0.82 STAT6 (0.51) CDK4CCND1CCND2CCND3FGFR4
SCHEMBL1284954 0.82 SYK (0.42) JAK3CDK4CCND1CCND3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088753-A1 PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2012-04-12 — — US claimed
EP-2403853-A1 PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS Medical Research Council Technology (GB) 2012-01-11 — — EP claimed
US-20120088753-A1 PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2012-04-12 — — US disclosed
EP-2403853-A1 PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS Medical Research Council Technology (GB) 2012-01-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088753-A1 PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS MARK3, MAPK8, CDK8 JAK3 20/4885CDK4 85/4885CCND1 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback